March 20, 2018 : DCMS #389

DISASTERS AVERTED — Near Miss Case Studies

Gut Reactions

EXCLUSIVE INTERVIEW — Candid Video Interviews with Top Practitioners

Swapnil N. Rajpathak Part 1, DPP-4 Inhibitors and Hypoglycemia

HOMERUN SLIDES — Great Clinical Presentation Highlights

Hypertension Update 2018 Part 2

CLINICAL GEMS — The Best from Diabetes Texts

International Textbook of Diabetes Mellitus, 4th Ed., Excerpt #117: Diabetes and Sleep Apnea Part 7

MOST POPULAR ARTICLES OF THE MONTH

#1 A Summary of ADA’s New 2018 Standards of Medical Care in Diabetes
#2 SGLT2 Inhibitors in Treatment of Type 1
#3 Meta-Analysis Evaluates Long-Term Safety of SGLT2’s

It is interesting that with all the medications we have for diabetes we often overlook the hypoglycemic effects. This is because we have moved away from the sulfonylureas, as they were always the ones that got blamed. This has opened many of our patients up to hypoglycemic effects from newer medications because we no longer stress the fear of low glucose levels.

This week Steve Freed sits down with Dr. Swapnil N. Rajpathak as he shares his insights into the use of one of the newer medications and the reduction of hypoglycemic risk.

Dave Joffe

Editor-in-chief

This is not one patient’s disaster averted but what I have experienced working in the field of diabetes and obesity for years.

Many times patients who are taking glucose lowering and/or anti obesity medications will report different GI complaints-such as bloating, diarrhea, constipation, nausea, vomiting, and GERD. They tell me they are going to see a gastroenterologist for an evaluation.

In part 1 of this Exclusive Interview, Dr. Swapnil N. Rajpathak talks with Diabetes in Control Publisher Steve Freed during the ADA 2017 Scientific Sessions in San Diego, CA about the contribution of the DPP4’s to the reduction of hypoglycemic risk.

In this week’s Homerun Slides, types of hypertension and defining Cushing’s Syndrome.

OSA and diabetes-related complications: Recently, there has been increasing interest in the association between OSA and diabetes-related complications. There is one cross-sectional published study regarding the association between OSA and macrovascular complications in T2DM, but several studies have examined the association between microvascular complications and OSA in T2DM. Most of these studies are cross-sectional in nature but more recently prospective studies proving causality have been published. Many of these studies fail to adjust for many of the possible confounders.

Comprehensive recommendations feature notable new recommendations for people with cardiovascular disease and diabetes.

Meta-analysis explores safety and efficacy of sodium-glucose co-transporter 2 inhibitors in patients with type 1 diabetes.

Short-term efficacy and safety of SGLT2 inhibitors have been well established, but what happens with long-lasting use of these medications?